EMA Authorised: Inrebic (fedratinib dihydrochloride monohydrate) — Bristol Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Inrebic for myeloproliferative neoplasms, including primary myelofibrosis, with Bristol Myers Squibb Pharma EEIG as the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Myeloproliferative Disorders;Primary Myelofibrosis. MAH: Bristol Myers Squibb Pharma EEIG. Decision date: 18/12/2025. Orphan medicine